V1RD6 Inhibitors
V1RD6 inhibitors encompass a range of chemical compounds that act on several pathways to effectively reduce the activity of V1RD6. For instance, inhibitors such as Trichostatin A target the fundamental level of chromatin structure and gene expression. By inhibiting histone deacetylase, Trichostatin A reduces the accessibility of the gene that codes for V1RD6, thus decreasing its expression. Similarly, Bortezomib, a proteasome inhibitor, stabilizes regulatory proteins that suppress V1RD6 expression, indirectly diminishing its activity. Compounds like LY294002 and Wortmannin exert their effects by targeting the PI3K/Akt pathway, which is integral for V1RD6 activation. Inhibition of PI3K results in a reduction of Akt-mediatedphosphorylation events, critical for V1RD6's functionality. This theme of pathway-targeted inhibition is reflected in the use of MEK inhibitors such as U0126 and PD98059, which thwart the MAPK/ERK pathway, thereby preventing ERK-mediated phosphorylation and activation of V1RD6. The p38 MAPK inhibitor SB203580 and the JNK inhibitor SP600125 serve a similar role in disrupting stress-responsive pathways that activate V1RD6.
Furthermore, the inhibition of upstream kinases by multi-kinase inhibitors such as Sorafenib, which targets RAF kinases within the RAF/MEK/ERK pathway, leads to a subsequent decrease in V1RD6 activation. The specific targeting of the EGFR by Erlotinib and Gefitinib also contributes to the downregulation of V1RD6 activity, as EGFR signaling is known to be an upstream activator of pathways involving V1RD6. Rapamycin's inhibition of mTOR complements this array of inhibitors by reducing the overall protein synthesis rate, which includes the synthesis of V1RD6, thereby achieving a decrease in its functional activity. Collectively, these inhibitors provide a multifaceted approach to dampening the effects of V1RD6 by interfering with various signaling pathways and regulatory mechanisms that are essential for its proper function and expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. V1RD6 activity is linked to chromatin remodeling, and by inhibiting histone deacetylase, Trichostatin A can result in a more condensed chromatin structure, thereby reducing the accessibility of the gene that codes for V1RD6, leading to its decreased expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. V1RD6 is a downstream effector in the PI3K/Akt pathway, and inhibition of PI3K can reduce the phosphorylation and activation of Akt, subsequently leading to a decrease in V1RD6 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Inhibition of mTOR can lead to reduced protein synthesis, and as V1RD6 is a protein, its levels can be decreased by rapamycin due to reduced translation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor. MEK is part of the MAPK/ERK pathway which influences the function of V1RD6. By inhibiting MEK, U0126 can prevent the activation of ERK, which is necessary for the phosphorylation and therefore the activity of V1RD6. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. V1RD6 may be activated by stress-responsive p38 MAPK signaling. Inhibiting p38 MAPK can thus reduce the activation of V1RD6 in response to cellular stress. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor, similar to U0126. By blocking MEK, PD98059 reduces ERK pathway signaling, therefore decreasing the phosphorylation and activation of V1RD6. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, like LY294002. It impairs the PI3K/Akt pathway, reducing Akt-mediated phosphorylation events that are critical for V1RD6 activation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It prevents the degradation of regulatory proteins that suppress V1RD6 expression. With these proteins stabilized, the expression and function of V1RD6 are reduced. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor. EGFR signaling can contribute to the activation of V1RD6. By inhibiting EGFR, Erlo tinib may decrease downstream signals that lead to the activation of V1RD6. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, like Erlotinib, is an EGFR inhibitor, and its mechanism in relation to V1RD6 is similar—blocking EGFR reduces the signaling cascade that activates V1RD6. | ||||||